BREGAL-MILESTONE
15.5.2024 06:01:36 CEST | Business Wire | Press release
Bregal Milestone, a leading European technology and software private equity firm, is pleased to announce the acquisition of Aktieinvest Incentives by its portfolio company, Allshares, a pioneering compensation and long-term incentive software and services provider. Following Allshares’ recent acquisition of Novare Pay, the strategic addition of Aktieinvest Incentives further establishes the company at the forefront of providing comprehensive compensation and incentive solutions in Sweden.
Aktieinvest Incentives is a leading provider of share plan and equity incentive administration to business customers in Sweden. Following the acquisition, Aktieinvest Incentives will fully integrate with Allshares’ state-of-the-art equity plan administration platform. Current Aktieinvest Incentives customers can expect uninterrupted service and will benefit from Allshares’ exceptional client support and end-to-end solutions, including expanded offerings like tax services and IFRS reporting.
In a statement from Louise Hagsten, CEO of Aktieinvest Incentives, the decision to integrate with Allshares was underscored by its unmatched holistic software and services offering. "Our partnership with Allshares heralds a new era of innovation and client-centricity for Aktieinvest Incentives customers. We were drawn to Allshares' commitment to excellence and their robust equity plan administration product suite which includes tax and IFRS reporting capabilities. We are confident that joining forces with Allshares will translate to an enhanced digital participant experience for Aktieinvest Incentives’ customers."
Erika Andersson, former CEO of Novare Pay and recently appointed CEO of Allshares Sweden, stated, “The reception of Allshares by Novare Pay customers and the broader Swedish market has been overwhelmingly positive. I am confident that Aktieinvest Incentives’ customers will have a similar experience, thanks to Allshares’ customer-centric and innovative approach to compensation solutions. The Allshares proposition stands out in the market, and I am eager to maintain our longstanding relationship with Aktieinvest Incentives’ customers. With Allshares, we can offer an enhanced equity plan administration proposition, further improving our ability to serve customers effectively.”
Pertti Helaniemi, CEO of Allshares Finland, highlighted the continuity and seamless experience that customers can expect from the addition of Aktieinvest Incentives to the Allshares ecosystem. "At Allshares, we are dedicated to maintaining high standards of service and innovation. In addition to Allshares’ comprehensive equity plan administration platform, our Pay Incentives, Pay Governance and Pay Analytics service offerings mean clients can expect a seamless one-stop experience for all their compensation needs."
John Hales, Managing Director at Bregal Milestone, reiterated the company's vision and the integral role that Aktieinvest Incentives plays in achieving it. "At Allshares, the vision is to deliver leading compensation solutions that drive high performance for both private and publicly listed customers throughout Europe. The acquisition of Aktieinvest Incentives is a testament to our commitment to this vision, as it strengthens our position as a leader in the Nordic region and reinforces our ability to deliver exceptional value to leading companies. We are thrilled to welcome Aktieinvest Incentives to the Allshares family and look forward to leveraging our combined strengths to deliver distinctive compensation solutions."
Terms of the transaction were not disclosed and are subject to customary closing conditions.
About Bregal Milestone
Bregal Milestone is a leading European software and technology private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €18 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2023. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Allshares
Allshares is a pioneering provider of compensation and incentive solutions in Europe. Trusted by leading multinational enterprises, Allshares will now serve approximately 900 clients in more than 60 countries with an end-to-end digital turnkey solution for equity plan management. Companies and participants can use its proprietary software and services to administer share plans in full compliance with relevant regulations, legal, and tax frameworks, as well as deliver seamless and automated IFRS reporting of share plans to companies. For more information, visit www.allshares.com.
About Aktieinvest
Aktieinvest Incentives is a part of Aktieinvest. Aktieinvest, among Sweden's oldest online brokers, boasts a 50-year legacy and 60,000 customers. Aktieinvest offers monthly share savings, dividend reinvestment, and handles corporate events, essentially simplifying stock investment. With a workforce of around 40, and a customer-centric approach, Aktieinvest has consistently sought to modernize and enhance its offerings, ensuring that clients can seamlessly save and invest in both Swedish and foreign stocks, funds, and ETFs. Since June 2023, Aktieinvest has been under the ownership of Söderberg & Partners, a prominent financial advisor and intermediary in the Nordic region. For more information, visit www.allshares.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514298200/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom